A Phase IIa, Multicenter, Randomized, Double-Blind, Parallel- Group, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of Orally Administered TU2670 in Subjects with Moderate to Severe Endometriosis-Associated Pain.
Latest Information Update: 13 May 2024
At a glance
- Drugs Merigolix (Primary)
- Indications Endometriosis; Pain
- Focus Proof of concept; Therapeutic Use
- Acronyms LUNA
- Sponsors TiumBio
- 08 May 2024 Primary endpoint (overall pelvic pain) has been met as per TiumBio media release.
- 08 May 2024 Results published in the TiumBio Media Release
- 08 May 2024 Status changed from recruiting to active, no longer recruiting per TiumBio media release.